Timber Pharmaceuticals, Inc.

0.49 USD
+0.14 (+41.86%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Timber Pharmaceuticals, Inc. stock is down -81.24% since 30 days ago. The next earnings date is Dec 12, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 10 November’s closed higher than October.

About Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals LLC engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders. BPX-01 is in Phase 3 topical minocycline for the. treatment of inflammatory lesions of acne vulgaris.